Retatrutide induced immune reprogramming both systemically and in the tumor microenvironment, with evidence of durable anti-tumor immunity including elevated circulating IL-6, increased antigen-presenting cells, reduced immunosuppressive cells, and activation of pro-inflammatory pathways
Curcumin Complex lowers inflammation that contributes to atherosclerosis
As of 2023, no GLP-1 transdermal systems have completed Phase 3 clinical trials or received regulatory approval
F., Boonpheng, B., Phemister, J., Hidalgo, J
GLP-1 medications reduce overall food intake, and many patients naturally reduce refined carbohydrate consumption as appetite suppression shifts food preferences toward higher-protein, lower-sugar options
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury